- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cybear, Mediconsult go public with merger plans
Cybear Group (part of Andrx Corporation) and Mediconsult.com have announced plans to merge in a stock-for-stock transaction. Under terms of the agreement, Mediconsult shares will be exchanged for Cybear shares at a ratio of 0.143 shares of
Cybear Group (part of Andrx Corporation) and Mediconsult.com have announced plans to merge in a stock-for-stock transaction. Under terms of the agreement, Mediconsult shares will be exchanged for Cybear shares at a ratio of 0.143 shares of Cybear stock for each share of Mediconsult. Subject to regulatory and shareholder approval, the firms expect to complete the merger in the second quarter. In the meantime, Cybear has agreed to provide interim financing to Mediconsult and to restructure its own company to reduce operating expenses. In a completely separate transaction, Cybear and Mediconsult's Physicians' Online Internet portal have entered into a strategic alliance.
In related news, Mediconsult plans to appeal Nasdaq's decision to delist Mediconsult's stock for not meeting the minimum net tangible assets requirement. Whether Mediconsult's potential delisting will affect the Cybear deal remains an open question. At press time, both Cybear and Mediconsult were trading well under $1 per share.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
